Tailored titration for flexible and accurate dosing1
Designed for Children
Sialanar® (400mcg/ml glycopyrronium bromide) is licensed for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) due to chronic neurological disorders of childhood onset in patients aged 3 years and older.1
See the SALIVA Trial - The first and only double-blind, randomised, placebo-controlled study of oral anticholinergics in sialorrhoea
that has investigated efficacy, safety and impact on quality of life2 continued as an open-label study extension3
Sialanar is Designed for Children
Due to a greater bioavailability, Sialanar® dose volumes are 20% lower than other glycopyrronium bromide oral solutions of the same concentration (2mg/5ml),1,4,5 helping to improve patient acceptability6
Minimal excipients to reduce toxicity risk - sugar, alcohol and sorbitol free1,7,8
Use the links below to explore
-
About Sialanar®
Sialanar® is designed for children, learn more about its features and why they make a difference. Find out more
-
Dosing and Titration
Head to this section to find out more about the dosing and titration schedule for Sialanar®. Find out more
-
Clinical Evidence
The first and only double-blind, randomised, placebo-controlled study of oral anticholinergics in sialorrhoea that has investigated efficacy, safety and impact on quality of life2,3 continued as an open-label study extension (OLSE)3 Find out more
-
Resources
Visit the resources section to find product support materials for patients/carers and educational resources for healthcare professionals. Find out more
-
Why treat drooling?
Did you know one population study found pneumonia is responsible for 39% of deaths in children with cerebral palsy.9
Sign up for Proveca Education Events
Proveca run educational sessions on a regular basis covering a variety of topics, register here by completing our 'contact us' form to be the first to know what’s coming up or head to our resources section to catch up on previous sessions.
